Jed Latkin, COO and CFO at NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB), bought 25,359 shares at $0.45 ($11K) on 2017-05-19, disclosed to the SEC on 2017-05-23.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.45 | 14,159 | $6K | 55.8% |
| 2 | $0.45 | 11,200 | $5K | 44.2% |
| Total | $0.45 avg | 25,359 | $11K | 100% |
| Filing → |
| NAVB | BUY | 2019-05-17 | $4K | — | Filing → |
| NAVB | BUY | 2019-05-15 | $10K | — | Filing → |
| NAVB | BUY | 2017-05-31 | $3K | — | Filing → |